Canada: Government Of Ontario Ban On Private Label Generics Is Upheld By Court Of Appeal

Last Updated: January 11 2012
Article by Jeffrey S. Graham and Bonnie Freedman

Most Read Contributor in Canada, September 2016

The complex market and regulatory framework for the sale of drugs in Ontario has been clarified, to some extent, by the recent decision of the Ontario Court of Appeal (Court) in an appeal by the Government of Ontario (Ontario) from two orders of the Ontario Divisional Court on applications brought by Shoppers Drug Mart and its affiliates ("Shoppers") and the Katz Group and its affiliates Pharma Plus and Rexall ("Katz"). The Court reversed the decision of the Divisional Court that had declared ultra-vires two sections of provincial regulations which effectively prohibit pharmacies from selling their "private-label" generic drugs (the "Regulations") in Ontario. A key factor in the decision was the Court's view that in a major public policy domain involving the intersection of health care and public finance, courts must exhibit "genuine restraint" in reviewing statutes and regulations and that the Divisional Court had not shown such restraint in this case.


In 2010 the conditions for listing a drug product under the Ontario Drug Benefit Act ("ODBA") and the Drug Interchangeability and Dispensing Fee Act ("DIDFA") (collectively the ODBA and the DIDFA will be referred to as the "Laws"), were amended to prohibit a drug product being designated as a "listed drug product" (i.e., eligible for reimbursement by Ontario under its public drug benefits program) if it was a "private label product". A private label product is defined in regulations made under the Laws as a drug product in respect of which the manufacturer is owned by a pharmacy but does not fabricate the product itself, is not controlled by the entity that fabricates the product or does not control the entity that fabricates the product. The existing structure established by Shoppers in other provinces (Sanis Health a subsidiary of Shoppers is a manufacturer) nor, presumably, the structure under consideration by Katz, met the limitations established in the Regulations. Shoppers and Katz argued that the Regulations:

a) fell outside the regulation-making authority granted to Ontario under the Laws because they purported to prohibit rather than regulate the listing of generic drug products and their designation as interchangeable with the brand name product; b) were inconsistent with the purpose of the Laws; and c) constituted an interference with their property and commercial rights in a manner not authorized by the Laws.

Shoppers and Katz also argued that the Regulations discriminate against private label manufacturers in a manner not authorized by the Laws.


The majority of the Court rejected the arguments of Shoppers and Katz. Justices MacPherson and Karakatsanis noted that legislative and regulatory changes to the Laws since 2006 have moved Ontario from a system in which pharmacies earned profits on the sale of drug products to a system that compensates pharmacies for a combination of products and services, including fees for dispensing and other professional services delivered to patients.

The majority concluded that the Regulations impose a condition for designating drug products as listed and interchangeable drug products, rather than constituting a prohibition. The Justices noted that because the Laws authorize regulations that impose conditions on generic drugs, they necessarily authorize the exclusion of drugs that do not meet the conditions. The majority noted that the Regulations do not prohibit Shoppers, Katz (or others) from participating in most of the activities in the fabricator/manufacturer/wholesaler/pharmacy/patient continuum of the Ontario drug supply chain including: continuing their large-scale and province-wide pharmacy businesses; fabricating drug products and selling them under their own labels; purchasing drugs from generic drug companies for the purpose of selling them under the generic companies' labels; and purchasing drugs from generic drug companies for resale under the generic companies' labels to other pharmacies.

As regards the issue of consistency with statutory purposes, the Justices noted that there is no dispute that the purpose of the Laws, having established a system called the Formulary for the recognition of the interchangeability of original or brand name drugs with their generic equivalents and for the listing of drugs covered by the Ontario Drug Benefits Plan is to allow pharmacists to be able to supply a prescribed drug in the cheapest form possible, both to persons who pay for the drugs themselves and to those who qualify to have the Government pay for their drugs. The majority accepted Ontario's submission that the Laws attempt to lower drug prices not only by directly regulating price, but also by indirectly regulating the compensation model of some participants in the drug supply system, with a focus on pharmacies. Unlike the Divisional Court, which focused on the impact of the Regulations on the business activities of pharmacies, the Court focused on the permissible compensation to pharmacies in the public drug system, accepting Ontario's linking of rebates (which prior to 2006 were paid to pharmacies by manufacturers as an incentive to stock their generic drug products) and the sale of private label products. The majority also accepted Ontario's position that instituting a new pharmacy reimbursement model, based on compensating pharmacies for professional services, is indispensible to achieving the purpose of the Laws and that permitting the sale of private label products would amount to the circumvention of the ban on payments from manufacturers to pharmacies from the resale of generic drugs (such as rebates). In this regard, the Laws provide detailed rules relating to compensation to pharmacies, including mark-up, dispensing fees, and professional allowances. The majority also accepted, while acknowledging that the actual effect of private labels on the market is hard to predict, that Ontario could reasonably conclude that private label products would reduce the competitiveness of the generic drug market, making future price reductions more difficult.

As regards the issue of interference with property and commercial rights, the majority noted that any interference with property or commercial rights was necessarily implied in the authority to set conditions for the listing of drugs as a benefit or as interchangeable under the Laws and as such, within the authority conferred on Ontario by the Laws.

Finally, the majority rejected the argument that the Regulations are discriminatory in an arbitrary or illegal sense, noting that under the Laws, the price of drug products depend on a variety of factors, including the timing of an application for interchangeability status and the public interest.


In a thoughtful dissent, Justice Epstein indicated that while she recognizes that Ontario could prohibit private label products by statute, she agrees with the Divisional Court that the Regulations are ultra vires.

First, Justice Epstein found that there is no rational connection between the Regulations and the purpose of the Laws. In this regard, she concluded that controlling the profitability of entities that own, operate or franchise pharmacies is not a legitimate object or purpose of the Laws, provided that it has no corresponding cost to the consumer, which she indicated was not the case in the current instance as there was no demonstrable connection between the common ownership of entities in the drug supply chain and lower drug prices. Second, Justice Epstein concluded that the intent of the Regulations was to prohibit pharmacies from earning profits through the ownership of manufacturers, and accordingly that the Regulations were designed and their effect is to prohibit rather than regulate. In this regard, Justice Epstein found that the focus on rebates and their impact on the price of drugs is not helpful to determining the issues. Third, she concluded that the Regulations interfere with commercial freedom and that the express language required to do so is not contained in the Laws. In this regard, she indicated that the authority to impose conditions for drug products to be listed and designated as interchangeable falls far short of express language authorizing interference with the right of one corporation to invest in another. Fourth, Justice Epstein found that the Regulations discriminate, in a manner not permitted by the Laws, against private label drug manufacturers and between different classes of corporations based on common ownership, when there is nothing in the Laws that specifically provides for the creation of different classes of drug manufacturers.


Although they have 60 days in which to request leave to appeal to the Supreme Court of Canada (i.e., February 20, 2012), the decision of the Court has likely brought to a conclusion the debate between Shoppers and Katz and Ontario as to whether private label products, as defined in the Regulations, will be permitted. To date, only Ontario has moved to prohibit private label products. The Court's decision may encourage other provincial governments to have a closer look at this issue. While provincial jurisdiction over the sale of drugs is not in doubt, on the issue of private label products, as on other issues, one can reasonably expect a greater level of coordination among governments in the future. The increasing pressure on all governments to control the cost of drug spending means that the debate over private label products is not the last complicated and controversial drug sector issue that will create tension between governments and private sector stakeholders that the courts will be asked to consider.

About BLG

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.